Benitec Biopharma (NASDAQ:BNTC) Upgraded to “Strong-Buy” at Leerink Partnrs

Leerink Partnrs upgraded shares of Benitec Biopharma (NASDAQ:BNTC) to a strong-buy rating in a research note published on Monday, Zacks.com reports. Leerink Partnrs also issued estimates for Benitec Biopharma’s Q4 2024 earnings at ($0.53) EPS, FY2024 earnings at ($5.45) EPS, FY2025 earnings at ($1.81) EPS and FY2026 earnings at ($1.83) EPS.

BNTC has been the topic of several other reports. JMP Securities lifted their target price on Benitec Biopharma from $10.00 to $16.00 and gave the stock a market outperform rating in a report on Monday, April 22nd. Piper Sandler assumed coverage on Benitec Biopharma in a report on Thursday, June 13th. They issued an overweight rating and a $30.00 target price on the stock. Finally, SVB Leerink started coverage on shares of Benitec Biopharma in a report on Monday. They set an outperform rating and a $13.00 price target for the company.

Benitec Biopharma Price Performance

NASDAQ BNTC opened at $9.27 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.18 and a current ratio of 4.18. Benitec Biopharma has a fifty-two week low of $1.86 and a fifty-two week high of $10.88. The business has a fifty day moving average price of $8.37 and a two-hundred day moving average price of $6.14.

Benitec Biopharma (NASDAQ:BNTC) last posted its earnings results on Monday, May 13th. The biotechnology company reported ($1.64) earnings per share for the quarter. As a group, research analysts anticipate that Benitec Biopharma will post -7.67 EPS for the current year.

Institutional Trading of Benitec Biopharma

An institutional investor recently raised its position in Benitec Biopharma stock. Janus Henderson Group PLC lifted its holdings in shares of Benitec Biopharma Inc. (NASDAQ:BNTC) by 35.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 244,491 shares of the biotechnology company’s stock after purchasing an additional 64,092 shares during the period. Janus Henderson Group PLC owned 9.44% of Benitec Biopharma worth $1,266,000 at the end of the most recent reporting period. 52.19% of the stock is owned by institutional investors and hedge funds.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.